Clinical Trial Update: A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is evaluating eplerenone for central serous chorioretinopathy and reports potential beneficial effects. The status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Serous Chorioretinopathy

Drugs mentioned

• eplerenone (eplerenone)

Snippet

Sponsor: Prim. Prof. Dr. Oliver Findl, MBA | Conditions: Central Serous Chorioretinopathy | Phase 2, Phase 3 | Status: UNKNOWN